The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
National Taiwan University Hospital
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00173199
First received: September 12, 2005
Last updated: November 29, 2005
Last verified: June 2005
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In order to increase our understanding about the pathogenic mechanism and the strategy of treatment in the subtypes of Guillain Barré syndrome, we will check the temporal changes of cytokines with different biological activities in serum and cerebrospinal fluid (CSF), check the titer of various anti-ganglioside antibodies, perform skin biopsy and correlate these data with the clinical findings such as severity and prognosis
| Condition |
|---|
|
Guillain Barré Syndrome |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation |
Resource links provided by NLM:
Genetics Home Reference related topics:
Guillain-Barré syndrome
MedlinePlus related topics:
Guillain-Barre Syndrome
U.S. FDA Resources
Further study details as provided by National Taiwan University Hospital:
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Progressive weakness of both legs and arms; areflexia; cranial nerve involvement (such as facial palsies); progression over days to 4 wks; recovery beginning 2-4 wks after progression ceases; elevated cerebrospinal fluid protein with <10 cells/µl; electrodiagnostic features of nerve conduction slowing or block.
Exclusion criteria:
- nil
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00173199
Contacts
| Contact: Sung-Tsang Hsieh, PhD | 886-2-23123456 ext 8182 | sthsieh@ha.mc.ntu.edu.tw |
Locations
| Taiwan | |
| Department of Anatomy and Cell Biology, National Taiwan University College of Medicine | Recruiting |
| Taipei, Taiwan | |
| Contact: Sung-Tsang Hsieh, PhD 886-2-23123456 ext 8182 sthsieh@ha.mc.ntu.edu.tw | |
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
| Study Director: | Sung-Tsang Hsieh, PhD | Department of Anatomy and Cell Biology, National Taiwan University College of Medicine; Department of Neurology, National Taiwan University Hospital |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00173199 History of Changes |
| Other Study ID Numbers: | 9461700526 |
| Study First Received: | September 12, 2005 |
| Last Updated: | November 29, 2005 |
| Health Authority: | Taiwan: Department of Health |
Additional relevant MeSH terms:
|
Guillain-Barre Syndrome Polyradiculoneuropathy Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases |
Peripheral Nervous System Diseases Neuromuscular Diseases Polyneuropathies Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on June 18, 2013